cerliponase alfa

Ukraine

Drugs containing this active substance

BRINEURA

The drug is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Form: solution for infusion

Active substance	Dosage
cerliponase alfa	30 mg/ml

Manufacturer: Wetter Pharma-Fertigung GmbH & Co. KG (finished medicinal product: processing of medicinal product and primary packaging (filling with finished medicinal product) and quality control testing (in-process control: identification, visual inspection, bioburden, and release testing: sterility, bacterial endotoxins), storage; irrigation solution: processing of medicinal product and primary packaging (filling with irrigation solution) and quality control testing (in-process control: identification, visual inspection, bioburden, release testing: sterility, bacterial endotoxins), storage)